DRTS | Alpha Tau Medical Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.9400 - 3.02
52 Week Range	1.7500 - 3.40
Beta	0.99
Implied Volatility	412.51%
IV Rank	29.29%
Day's Volume	82,747
Average Volume	30,582
Shares Outstanding	69,924,200
Market Cap	209,772,600
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-03-08

Valuation
Profitability
Growth
Health
P/E Ratio	-6.98
Forward P/E Ratio	N/A
EPS	-0.43
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	121
Country	Israel
Website	DRTS

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

DRTS's peers: CLSD, EYEN, OCUL, TNYA, INZY, MNOV, ELYM, MOLN, CSBR, CYT, GNFT, ERYP, HCWB, DRTSW

*Chart delayed

Analyzing fundamentals for DRTS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see DRTS Fundamentals page.

Watching at DRTS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on DRTS Technicals page.